Global Transdermal Patch Market & Clinical Pipeline Outlook 2022

Date: March 1, 2017
Pages: 260
Price:
US$ 2,400.00
License [?]:
Publisher: Kuick Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery
ID: GEC399D2AEBEN
Leaflet:

Download PDF Leaflet

Global Transdermal Patch Market & Clinical Pipeline Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Transdermal Patch Market & Clinical Pipeline Outlook 2022” report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies. Currently there 40 transdermal patches available in the market and more than 70 patches are in clinical pipeline.

Transdermal patches have made their place in global market in past few decades as an alternative to conventional therapeutic for various disease indications. Systemic drug delivery could be achieved by oral and prenatal methods but they have several limitations due to which many patients often find them inconvenient. Pharmaceutical companies have identified these problems as an opportunity to develop transdermal patches for generating significant revenues. This problem was identified early and advancements in biotechnology helped in the introduction of transdermal patches in global market. Nowadays, they are available for different disease indications and generally found suitable for large number of people having different disease indications. As a result, numbers of users are escalating at tremendous rates which are steadily increasing the global size.

Transdermal patches are widely accepted among physicians and patients due to their non-invasive, pain free and easy administration. In recent years, the growth of transdermal patch market has increased and expected to increase significantly in coming years. Higher investments in research and development could be attributed to the success of transdermal patch market. Number of disease indication treated by them is increasing steadily leading to higher market penetration. Every year various transdermal patches are introduced in globally leading to increased market size.

Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.

Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment. Before marketing approval they have to undergo strict testing and checking for various qualitative parameters. They must be stable, chemically unreactive, hypo allergic, nontoxic and easy to manufacture. High throughput methods are expected to increase the suitable polymer screening rates along with reduced time consumption. Bioequivalence of therapeutic in transdermal patch with same drug administrated via different route have known efficacy must be shown. Similarly, independent of patch type they must show bioequivalence in clinical trials before getting marketing approval from medical regulatory authorities. Various products are at different stages of clinical trials which will be introduced in global market in coming years.

“Global Transdermal Patch Market & Clinical Pipeline Outlook 2022” report highlights:
  • Introduction & Classification of Transdermal Patch
  • Mechanism of Transdermal Patch Drug Delivery
  • Transdermal Patch v/s Traditional Drug Delivery Methods
  • Global Transdermal Patch Clinical Pipeline Overview
  • Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase
  • Global Transdermal Patch Market Future Prospects
1. INTRODUCTION TO TRANSDERMAL PATCH

2. CLASSIFICATION OF TRANSDERMAL PATCHES

2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch

3. WHY THERE EXIST NEED FOR TRANSDERMAL PATCHES?

4. MECHANISM OF TRANSDERMAL PATCH DRUG DELIVERY

4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch

5. TRANSDERMAL PATCH V/S TRADITIONAL DRUG DELIVERY METHODS

6. GLOBAL TRANSDERMAL PATCH MARKET OUTLOOK

6.1 Global Market Scenario
6.2 Regional Trends

7. GLOBAL TRANSDERMAL PATCH CLINICAL PIPELINE OVERVIEW

7.1 By Phase
7.2 By Region/Country
7.3 By Drug Class/Molecule
7.4 By Company
7.5 By Orphan & Fast Track Status
7.6 By Mode of Action

8. GLOBAL TRANSDERMAL PATCH MARKET DYNAMICS

8.1 Favorable Market Parameters
8.2 Commercialization Challenges

9. GLOBAL TRANSDERMAL PATCH MARKET FUTURE PROSPECTS

10. GLOBAL TRANSDERMAL PATCH CLINICAL INSIGHT

10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered

11. MARKETED TRANSDERMAL PATCH CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE

12. COMPETITIVE LANDSCAPE

12.1 3M Pharmaceuticals
12.2 Acrux
12.3 Agile Therapeutics
12.4 Allergan
12.5 ANI Pharmaceuticals
12.6 Antares Pharma
12.7 Bayer HealthCare Pharmaceuticals
12.8 Corium International
12.9 Chase Pharmaceuticals
12.10 DURECT Corporation
12.11 Endo Pharmaceuticals
12.12 Fempharm
12.13 Hisamitsu Pharmaceutical
12.14 Immune Pharmaceuticals
12.15 Imprimis Pharmaceuticals
12.16 Ipsen Bioscience
12.17 Johnson & Johnson
12.18 LaSalle Laboratories
12.19 Lavipharm-increase
12.20 MINRAD International
12.21 NeurogesX
12.22 Noven Pharmaceuticals
12.23 NuPathe
12.24 Nuvo Research
12.25 Novartis
12.26 Pain Therapeutics
12.27 ProStrakan
12.28 Purdue Pharma
12.29 Sanofi
12.30 Scilex Pharmaceuticals
12.31 Senju Pharmaceutical
12.32 Somerset Pharmaceuticals
12.33 Teikoku Seiyaku
12.34 Therapeutic Discovery Corporation
12.35 Transdermal Delivery Solutions Corp
12.36 UCB-full form
12.37 Xel Pharmaceuticals
12.38 Zosano Pharma

LIST OF FIGURES

Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 4-1: Properties of Transdermal Therapeutics
Figure 4-2: Components of Transdermal Patch
Figure 4-3: Types of Permeation Enhancers
Figure 4-4: Schematic Representation of Iontophoresis
Figure 4-5: Mechanism of Scopolamine Transdermal Patch
Figure 4-6: Mechanism of Nicotine Transdermal Patch
Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 5-1: Issues with Traditional Drug Delivery Methods
Figure 5-2: Advantages of Transdermal Patch
Figure 5-3: Consistent Drug Supply by Transdermal Patch
Figure 6-1: Global – Transdermal Patch Market Opportunity (US$ Billion), 2016-2022
Figure 7-1: Global – Transdermal Patch Pipeline by Phase (%), 2017 till 2022
Figure 7-2: Global – Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
Figure 7-3: Global – Transdermal Patch Pipeline by Phase (%), 2017 till 2022
Figure 7-4: Global – Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
Figure 7-5: Global - Transdermal Patch Pipeline by Region (%), 2017 till 2022
Figure 7-6: Global - Transdermal Patch Pipeline by Country (%), 2017 till 2022
Figure 7-7: Global - Transdermal Patch Pipeline by Drug Class/Molecule (%), 2017 till 2022
Figure 7-8: Global - Transdermal Patch Pipeline by Company (%), 2017 till 2022
Figure 7-9: Global - Transdermal Patch Pipeline by Ophan & Fast Track Status (%), 2017 till 2022
Figure 7-10: Global - Transdermal Patch Pipeline by Mode of Action (%), 2017 till 2022
Figure 8-1: Drivers for Transdermal Patch
Figure 8-2: Transdermal Patch Market Commercialization Challenges
Figure 12-1: Acrux Clinical Pipeline
Figure 12-2: Agile Therapeutics Clinical Pipeline
Figure 12-3: Antares Pharma Clinical Pipeline
Figure 12-4: Corium International Clinical Pipeline
Figure 12-5: Durect Corporation Clinical Pipeline
Figure 12-6: Endo Pharmaceuticals Clinical Pipeline
Figure 12-7: Immune Pharmaceuticals Clinical Pipeline
Figure 12-8: Novartis Clinical Pipeline
Figure 12-9: Senju Pharmaceuticals Clinical Pipeline
Figure 12-10: Xel Pharamaceuticals Clinical Pipeline
Figure 12-11: Zosano Pharma Clinical Pipeline

LIST OF TABLES

Table 2-1: Differences between Active & Passive Transdermal Patches
Table 4-1: Transdermal Patches for Various Disease Indications
Table 12-1: Pain Therapeutics Clinical Pipeline
Skip to top


Ask Your Question

Global Transdermal Patch Market & Clinical Pipeline Outlook 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: